Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Oncology Research and Treatment|June 17, 2020
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer SocietyLothar Bergmann, Viktor Grünwald, Luise Maute, et al.
Oncology Research and Treatment|January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO StudyPeter J Goebell, Edwin Hermann, Ulrich Kube, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
Urologic Oncology|January 24, 2025
Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Urologia Internationalis|February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature ReviewAnnemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
The Prostate|July 11, 2024
Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancerMike Wenzel, Nele Wagner, Benedikt Hoeh, et al.
Deutsches Arzteblatt International|June 24, 2025
Radical Prostatectomy Versus Radiotherapy for Prostate Cancer: Stage-, Age-, and Frailty-Specific Cancer-Control Outcomes of 2600 PatientsMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 6, 2025
Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomyMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
BMC Cancer|May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyLothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Pageof 7